A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoechst Marion Roussel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Prior antiretroviral agents for up to 6 months per agent.
Patients must have:
HIV infection.
Asymptomatic or mildly symptomatic.
CD4 count 301 - 500 cells/mm3.
You may not be if
Co-existing Condition:
Patients with the following condition are excluded:
Unable or unwilling to comply with study procedures.
Concurrent Medication:
Excluded:
Chemoprophylactic therapy for mycobacterial infection.
Any nonstudy prescription medications without approval of investigator.
Patients with the following prior conditions are excluded:
History of grade 3 or 4 toxicity to \<= 600 mg/day AZT.
History of intolerance to lactose.
Chronic diarrhea within 6 months prior to study entry.
Unexplained intermittent or chronic fever, defined as temperature \>= 38.5 C for any 7 days within the 30 days prior to study entry.
Prior Medication:
Excluded:
Antiretroviral therapy within 2 weeks prior to study entry.
Prior HIV vaccines.
Biological response modifiers within 30 days prior to study entry.
Prior foscarnet.
Any investigational drug with a washout \< 5 half-lives prior to study entry.
Any medications known to alter renal, hepatic, or hematologic / immunologic function (such as barbiturates, phenothiazines, cimetidine, immunomodulators, etc.) within 14 days prior to study entry.
Recent history of alcohol and/or drug abuse.
Clareo Health | A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
